第五章 結論與建議
5.3 未來研究方向
本研究採用的健保資料庫資料有大樣本且具代表性的優點，但也如上述所提 出之研究限制，我們可以看到本研究仍有許多研究限制尚須改進，舉例來說，抽 菸、酗酒等相關風險因子若能一併考慮進本研究中，並在探討慢性腎臟病與梅尼 爾氏症之間的風險關係時，能夠予以校正，如此，所提出的研究結果會更有可性 力與精確性，再者，若能取得病患的臨床生化值，那麼對於進一步疾病探討的準 確度與關係機制可能有進一層探討的可能性，當然的在本研究中，慢性腎臟病引 發梅尼爾氏症的假設情況，雖有樣本統計數據的證明，而更明確的內在因素、機 制的探討上卻也有許多問題需要進一步被探討與了解。
在本研究中，未來尚需要進行考量的部分還有下列幾點：
一、 在合併症的校正上，於章節 1.5.2 中所蒐集的文獻提到梅尼爾氏症的風險 因子中還包含了過敏、病毒性感染在本研究中並未被考慮校正，原因在於 過敏、病毒性感染所包含的疾病範圍也相當的廣，因此在未來，關於這兩 項因子與梅尼爾氏症有所相關的文獻蒐集以及進一步校正也應該被包含 於此慢性腎臟病與梅尼爾氏症風險關係的研究中。
二、 於本研究中屬於自身免疫性疾病的皮肌炎以及多發性肌炎的人數有較少 的情況，人數較少的合併症是否應被考慮包含於本研究中且是否具有討論 統計分析的意義，在未來人數過少的合併症是否應該移除也是需要進一步 考慮的一項問題之一。
三、 在本研究 1.5 相關研究探討章節中，我們提到一些藥物的使用，像是利尿 劑使用於慢性腎臟病患用於治療水腫，慶大霉素用於腹膜透析病患的腹膜 炎感染問題等，這些藥物的使用可能會導致耳毒性，像是眩暈、聽力損失、
耳鳴等類似梅尼爾氏症的症狀，而這些藥物於腎病患中的使用是否有可能 是導致梅尼爾氏症的發生因素，在未來的研究中也可一併使用健保資料庫 所擁有的藥物檔進行分析討論。
66
參考文獻
1. National Kidney, F., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002.
39(2 Suppl 1): p. S1-266.
2. Sarnak, M.J., et al., Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 2003.
42(5): p. 1050-65.
3. Ruggenenti, P., et al., Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet, 1998. 352(9136): p. 1252-6.
4. Ruggenenti, P., et al., Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, 1999.
354(9176): p. 359-64.
5. von Vigier, R.O., et al., Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. Eur J Pediatr, 2000. 159(8): p.
590-3.
6. Williams, H.L., Meniere's disease; medical treatment. J Mich State Med Soc, 1952. 51(5): p. 572-6.
7. Minor, L.B., D.A. Schessel, and J.P. Carey, Meniere's disease. Curr Opin Neurol, 2004. 17(1): p. 9-16.
8. Peron, D.L., et al., Clinical and experimental results with focused ultrasound.
Laryngoscope, 1983. 93(9): p. 1217-21.
9. Wladislavosky-Waserman, P., et al., Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980. Laryngoscope, 1984. 94(8): p. 1098-102.
10. Havia, M., E. Kentala, and I. Pyykko, Prevalence of Meniere's disease in general population of Southern Finland. Otolaryngol Head Neck Surg, 2005.
133(5): p. 762-8.
11. Watanabe, Y., et al., Epidemiological and clinical characteristics of Meniere's disease in Japan. Acta Otolaryngol Suppl, 1995. 519: p. 206-10.
12. Paparella, M.M., The cause (multifactorial inheritance) and pathogenesis (endolymphatic malabsorption) of Meniere's disease and its symptoms
67
(mechanical and chemical). Acta Otolaryngol, 1985. 99(3-4): p. 445-51.
13. Vrabec, J.T., L.M. Simon, and N.J. Coker, Survey of Meniere's disease in a subspecialty referral practice. Otolaryngol Head Neck Surg, 2007. 137(2): p.
213-7.
14. Kitahara, M., Bilateral aspects of Meniere's disease. Meniere's disease with bilateral fluctuant hearing loss. Acta Otolaryngol Suppl, 1991. 485: p. 74-7.
15. Hallpike, C.S. and H. Cairns, Observations on the Pathology of Meniere's Syndrome: (Section of Otology). Proc R Soc Med, 1938. 31(11): p. 1317-36.
16. Chung, J.W., et al., Histopathology after endolymphatic sac surgery for Meniere's syndrome. Otol Neurotol, 2011. 32(4): p. 660-4.
17. Albers, F.W., R. Van Weissenbruch, and J.W. Casselman, 3DFT-magnetic resonance imaging of the inner ear in Meniere's disease. Acta Otolaryngol, 1994. 114(6): p. 595-600.
18. Shea, J.J., Jr., et al., External aperture of the vestibular aqueduct in Meniere's disease. Am J Otol, 2000. 21(3): p. 351-5.
19. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg, 1995. 113(3): p. 181-5.
20. Kitahara, M., et al., Pathophysiology of Meniere's disease and its subvarieties.
Acta Otolaryngol Suppl, 1984. 406: p. 52-5.
21. Kinney, S.E., S.A. Sandridge, and C.W. Newman, Long-term effects of Meniere's disease on hearing and quality of life. Am J Otol, 1997. 18(1): p.
67-73.
22. Jackson, C.G., et al., Medical management of Meniere's disease. Ann Otol Rhinol Laryngol, 1981. 90(2 Pt 1): p. 142-7.
23. Klockhoff, I. and U. Lindblom, Meniere's disease and hydrochlorothiazide (Dichlotride)--a critical analysis of symptoms and therapeutic effects. Acta Otolaryngol, 1967. 63(4): p. 347-65.
24. van Deelen, G.W. and E.H. Huizing, Use of a diuretic (Dyazide) in the treatment of Meniere's disease. A double-blind cross-over placebo-controlled study. ORL J Otorhinolaryngol Relat Spec, 1986. 48(5): p. 287-92.
25. Barrs, D.M., et al., Intratympanic steroid injections for intractable Meniere's disease. Laryngoscope, 2001. 111(12): p. 2100-4.
26. Parnes, L.S., A.H. Sun, and D.J. Freeman, Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.
Laryngoscope, 1999. 109(7 Pt 2): p. 1-17.
68
27. Shea, J.J., Jr. and X. Ge, Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Meniere's disease. Otolaryngol Clin North Am, 1996. 29(2): p. 353-8.
28. Brown, J.S., A ten year statistical follow-up of 245 consecutive cases of endolymphatic shunt and decompression with 328 consecutive cases of labyrinthectomy. Laryngoscope, 1983. 93(11 Pt 1): p. 1419-24.
29. Glasscock, M.E., 3rd, et al., Medical and surgical management of Meniere's disease. Am J Otol, 1984. 5(6): p. 536-42.
30. Glasscock, M.E., 3rd, et al., An analysis of the retrolabyrinthine vs. the retrosigmoid vestibular nerve section. Otolaryngol Head Neck Surg, 1991.
104(1): p. 88-95.
31. Schuknecht, H.F., Ablation therapy in the management of Meniere's disease.
Acta Otolaryngol Suppl, 1957. 132: p. 1-42.
32. Blakley, B.W., Update on intratympanic gentamicin for Meniere's disease.
Laryngoscope, 2000. 110(2 Pt 1): p. 236-40.
33. Cheng, C.L., et al., Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf, 2011. 20(3): p. 236-42.
34. Lai, M.N., et al., Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid.
Nephrology (Carlton), 2009. 14(2): p. 227-34.
35. Wu, C.Y., et al., Effective Reduction of Gastric Cancer Risk With Regular Use of Nonsteroidal Anti-Inflammatory Drugs in Helicobacter Pylori-Infected Patients.
Journal of Clinical Oncology, 2010. 28(18): p. 2952-2957.
36. Chiu, H.F., et al., Statin Use and the Risk of Liver Cancer: A Population-Based Case-Control Study. American Journal of Gastroenterology, 2011. 106(5): p.
894-898.
37. Kuo, H.W., et al., Epidemiological features of CKD in Taiwan. Am J Kidney Dis, 2007. 49(1): p. 46-55.
38. Sheu, J.J., et al., Hyperthyroidism and Risk of Ischemic Stroke in Young Adults A 5-Year Follow-Up Study. Stroke, 2010. 41(5): p. 961-966.
39. Su, S.L., et al., Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population. J Renin Angiotensin Aldosterone Syst, 2012. 13(1): p.
148-54.
40. Yildiz, I., et al., International evaluation of unrecognizably uglifying human faces in late and severe secondary hyperparathyroidism in chronic kidney
69
disease. Sagliker syndrome. A unique catastrophic entity, cytogenetic studies for chromosomal abnormalities, calcium-sensing receptor gene and GNAS1 mutations. Striking and promising missense mutations on the GNAS1 gene exons 1, 4, 10, 4. J Ren Nutr, 2012. 22(1): p. 157-61.
41. Meguid El Nahas, A. and A.K. Bello, Chronic kidney disease: the global challenge. Lancet, 2005. 365(9456): p. 331-40.
42. Coresh, J., et al., Prevalence of chronic kidney disease in the United States.
JAMA, 2007. 298(17): p. 2038-47.
43. Couser, W.G., Chronic kidney disease the promise and the perils. J Am Soc Nephrol, 2007. 18(11): p. 2803-5.
44. Imai, E., et al., Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol, 2007. 11(2): p. 156-63.
45. Wen, C.P., et al., All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet, 2008.
371(9631): p. 2173-82.
46. Quick, C.A., A. Fish, and C. Brown, The relationship between cochlea and kidney. Laryngoscope, 1973. 83(9): p. 1469-82.
47. He, Q.Y., et al., G8: a novel domain associated with polycystic kidney disease and non-syndromic hearing loss. Bioinformatics, 2006. 22(18): p. 2189-91.
48. Agarwal, S.K. and A. Gupta, Aquaporins: The renal water channels. Indian J Nephrol, 2008. 18(3): p. 95-100.
49. Stankovic, K.M., J.C. Adams, and D. Brown, Immunolocalization of aquaporin CHIP in the guinea pig inner ear. Am J Physiol, 1995. 269(6 Pt 1): p. C1450-6.
50. Eckhard, A., et al., Water channel proteins in the inner ear and their link to hearing impairment and deafness. Mol Aspects Med, 2012. 33(5-6): p.
612-37.
51. Candreia, C., N. Schmuziger, and N. Gurtler, Molecular analysis of aquaporin genes 1 to 4 in patients with Meniere's disease. Cell Physiol Biochem, 2010.
26(4-5): p. 787-92.
52. Deen, P.M., et al., Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science, 1994. 264(5155): p.
92-5.
53. van Lieburg, A.F., et al., Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene.
Am J Hum Genet, 1994. 55(4): p. 648-52.
54. King, L.S. and P. Agre, Pathophysiology of the aquaporin water channels. Annu
70
Rev Physiol, 1996. 58: p. 619-48.
55. Holmes, R.P., The role of renal water channels in health and disease. Mol Aspects Med, 2012. 33(5-6): p. 547-52.
56. Lange, G. and R. Keller, Loss of peripheral vestibular function. Twenty cases of Dandy's syndrome. Laryngo-Rhino-Otologie, 2000. 79(2): p. 77-80.
57. Verdel, B.M., et al., Drug-related nephrotoxic and ototoxic reactions : a link through a predictive mechanistic commonality. Drug Saf, 2008. 31(10): p.
877-84.
58. Shaheen, F.A., et al., Reversible uremic deafness: is it correlated with the degree of anemia? Ann Otol Rhinol Laryngol, 1997. 106(5): p. 391-3.
59. Albertazzi, A., et al., The natural history of uremic neuropathy. Contrib Nephrol, 1988. 65: p. 130-7.
60. Di Paolo, B., et al., Electrophysiological aspects of nervous conduction in uremia. Clin Nephrol, 1988. 29(5): p. 253-60.
61. Hutter, J.C., et al., Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers. JAMA, 2000. 283(16): p.
2128-34.
62. Lasisi, O.A., et al., Sudden sensorineural hearing loss and hemodialysis. Ear Nose Throat J, 2006. 85(12): p. 819-21.
63. Rizvi, S.S. and R.A. Holmes, Hearing loss from hemodialysis. Arch Otolaryngol, 1980. 106(12): p. 751-6.
64. Moffat, D.A., V.L. Cumberworth, and D.M. Baguley, Endolymphatic hydrops precipitated by haemodialysis. J Laryngol Otol, 1990. 104(8): p. 641-2.
65. Van den Neucker, K., G. Vanderstraeten, and R. Vanholder, Peripheral motor and sensory nerve conduction studies in haemodialysis patients. A study of 54 patients. Electromyogr Clin Neurophysiol, 1998. 38(8): p. 467-74.
66. Ackil, A.A., et al., Late response and sural conduction studies. Usefulness in patients with chronic renal failure. Arch Neurol, 1981. 38(8): p. 482-5.
67. Nielsen, V.K., The peripheral nerve function in chronic renal failure. V. Sensory and motor conduction velocity. Acta Med Scand, 1973. 194(5): p. 445-54.
68. Anteunis, L.J. and J.M. Mooy, Hearing loss in a uraemic patient: indications of involvement of the VIIIth nerve. J Laryngol Otol, 1987. 101(5): p. 492-6.
69. Thornton, A.R. and G. Farrell, Apparent travelling wave velocity changes in cases of endolymphatic hydrops. Scand Audiol, 1991. 20(1): p. 13-8.
70. Maekawa, C., et al., Expression and translocation of aquaporin-2 in the endolymphatic sac in patients with Meniere's disease. J Neuroendocrinol, 2010. 22(11): p. 1157-64.
71
71. Steinbach, S., et al., Effect of thirst challenge on ADH levels in patients with bilateral Meniere's disease. Exp Clin Endocrinol Diabetes, 2012. 120(7): p.
405-9.
72. Chong, T.K., B. Piraino, and J. Bernardini, Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int, 1991. 11(2): p. 152-5.
73. Sennesael, J., D. Verbeelen, and S. Lauwers, Ototoxicity associated with cephalexin in two patients with renal failure. Lancet, 1982. 2(8308): p. 1154-5.
74. Ramsden, R.T. and P. Ackrill, Bobbing oscillopsia from gentamicin toxicity. Br J Audiol, 1982. 16(2): p. 147-50.
75. Tokgoz, B., et al., Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD. Ren Fail, 2010. 32(2): p. 179-84.
76. Goldstein, L.B., et al., Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council:
cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group:
the American Academy of Neurology affirms the value of this guideline. Stroke, 2006. 37(6): p. 1583-633.
77. Neely, J.G., Clinical experience with a surgical approach to hydrops. Ann N Y Acad Sci, 2001. 942: p. 322-7.
78. Arnold, W., et al., The influence of measles vaccination on the incidence of otosclerosis in Germany. Eur Arch Otorhinolaryngol, 2007. 264(7): p. 741-8.
79. Kuhle, S., et al., The association between childhood overweight and obesity and otitis media. Pediatr Obes, 2012. 7(2): p. 151-7.
80. Liu, J.H., et al., The risk for chronic kidney disease in patients with heart diseases: a 7-year follow-up in a cohort study in Taiwan. BMC Nephrol, 2012.
13: p. 77.
81. Wu, C.Y., et al., Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer, 2011. 117(3): p. 618-24.
82. Lin, G.M., et al., Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in taiwan, 1997-2009.
Schizophr Bull, 2013. 39(2): p. 407-16.
83. Chen, Y.J., et al., Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol, 2012. 148(1): p. 103-8.
84. Chen, Y.J., et al., Comorbidity profiles among patients with bullous
72
pemphigoid: a nationwide population-based study. Br J Dermatol, 2011.
165(3): p. 593-9.
85. Shojaku, H., et al., Epidemiological study of severe cases of Meniere's disease in Japan. Acta Otolaryngol Suppl, 1995. 520 Pt 2: p. 415-8.
86. Paparella, M.M. and B.P. Kimberley, Pathogenesis of Meniere's disease. J Vestib Res, 1990. 1(1): p. 3-7.
87. Yamamoto, E., C. Mizukami, and M. Ohmura, Investigation of the external aperture of the vestibular aqueduct in Meniere's disease by three-dimensional image analysis. Acta Otolaryngol, 1992. 112(1): p. 31-5.
88. Yazawa, Y. and M. Kitahara, Computed tomographic findings around the vestibular aqueduct in Meniere's disease. Acta Otolaryngol Suppl, 1991. 481:
p. 88-90.
89. Huang, T.S. and C.C. Lin, Surgical treatment of chronic otitis media and Meniere's syndrome. Laryngoscope, 1991. 101(8): p. 900-4.
90. Paparella, M.M., Pathogenesis and pathophysiology of Meniere's disease.
Acta Otolaryngol Suppl, 1991. 485: p. 26-35.
91. Beyea, J.A., S.K. Agrawal, and L.S. Parnes, Recent advances in viral inner ear disorders. Curr Opin Otolaryngol Head Neck Surg, 2012. 20(5): p. 404-8.
92. Haid, C.T., et al., Clinical survey of Meniere's disease: 574 cases. Acta Otolaryngol Suppl, 1995. 520 Pt 2: p. 251-5.
93. Spencer, J.T., Jr., Hyperlipoproteinemia, hyperinsulinism, and Meniere's disease. South Med J, 1981. 74(10): p. 1194-7, 1200.
94. D'Avila, C. and L. Lavinsky, Glucose and insulin profiles and their correlations in Meniere's disease. Int Tinnitus J, 2005. 11(2): p. 170-6.
95. Paparella, M.M., et al., Otological manifestations of leukemia. Laryngoscope, 1973. 83(9): p. 1510-26.
96. Sando, I. and T. Egami, Inner ear hemorrhage and endolymphatic hydrops in a leukemic patient with sudden hearing loss. Ann Otol Rhinol Laryngol, 1977.
86(4 Pt 1): p. 518-24.
97. Nacci, A., et al., Elevated antithyroid peroxidase and antinuclear autoantibody titers in Meniere's disease patients: more than a chance association? Audiol Neurootol, 2010. 15(1): p. 1-6.
98. Riente, L., et al., Antibodies to inner ear antigens in Meniere's disease. Clin Exp Immunol, 2004. 135(1): p. 159-63.
99. Greco, A., et al., Meniere's disease might be an autoimmune condition?
Autoimmun Rev, 2012. 11(10): p. 731-8.
100. McCabe, B.F., Autoimmune sensorineural hearing loss. Ann Otol Rhinol
73
Laryngol, 1979. 88(5 Pt 1): p. 585-9.
101. Hughes, G.B., et al., Autoimmune reactivity in Meniere's disease: a preliminary report. Laryngoscope, 1983. 93(4): p. 410-7.
102. Dornhoffer, J.L. and I.K. Arenberg, Immune mechanisms in Meniere's syndrome. Otolaryngol Clin North Am, 1997. 30(6): p. 1017-26.
103. Bovo, R., A. Ciorba, and A. Martini, Vertigo and autoimmunity. Eur Arch Otorhinolaryngol, 2010. 267(1): p. 13-9.
104. Yoo, T.J., et al., Type II collagen-induced autoimmune endolymphatic hydrops in guinea pig. Science, 1983. 222(4619): p. 65-7.
105. Yoo, T.J., Etiopathogenesis of Meniere's disease: a hypothesis. Ann Otol Rhinol Laryngol Suppl, 1984. 113: p. 6-12.
106. Brookes, G.B., Circulating immune complexes in Meniere's disease. Arch Otolaryngol Head Neck Surg, 1986. 112(5): p. 536-40.
107. Yoo, T.J., et al., Presence of autoantibodies in the sera of Meniere's disease.
Ann Otol Rhinol Laryngol, 2001. 110(5 Pt 1): p. 425-9.
108. Wackym, P.A., et al., Human endolymphatic sac: morphologic evidence of immunologic function. Ann Otol Rhinol Laryngol, 1987. 96(3 Pt 1): p. 276-81.
109. Johnson, D.W. and R.H. Mathog, Hearing function and chronic renal failure.
Ann Otol Rhinol Laryngol, 1976. 85(1 Pt 1): p. 43-9.
110. Kusakari, J., et al., The inner ear dysfunction in hemodialysis patients. Tohoku J Exp Med, 1981. 135(4): p. 359-69.
111. Gloddek, B. and W. Arnold, Clinical and experimental studies of autoimmune inner ear disease. Acta Otolaryngol Suppl, 2002(548): p. 10-4.
112. Bernstein, J.M., T.C. Shanahan, and F.M. Schaffer, Further observations on the role of the MHC genes and certain hearing disorders. Acta Otolaryngol, 1996.
116(5): p. 666-71.
113. Shojaku, H., et al., Epidemiologic characteristics of definite Meniere's disease in Japan. A long-term survey of Toyama and Niigata prefectures. ORL J Otorhinolaryngol Relat Spec, 2005. 67(5): p. 305-9.
114. Shojaku, H., et al., Changes in the characteristics of definite Meniere's disease over time in Japan: a long-term survey by the Peripheral Vestibular Disorder Research Committee of Japan, formerly the Meniere's Disease Research Committee of Japan. Acta Otolaryngol, 2009. 129(2): p. 155-60.
115. Vibert, D., M. Caversaccio, and R. Hausler, Meniere's disease in the elderly.
Otolaryngol Clin North Am, 2010. 43(5): p. 1041-6.
116. Ballester, M., et al., Meniere's disease in the elderly. Otol Neurotol, 2002.
23(1): p. 73-8.
74
117. Lee, H., et al., Drop attacks in elderly patients secondary to otologic causes with Meniere's syndrome or non-Meniere peripheral vestibulopathy. J Neurol Sci, 2005. 232(1-2): p. 71-6.